MapLight Therapeutics, Inc. MPLT
7.25 USD 0.00 (+0.00%)
Regular-session close
7.34 +0.09 +1.24%
Pre-market · Nov 16, 8:33 AM ET
6.95 Day range 7.38
6.06 52-week range 40.43
- YTD
- -58.74%
- 1 year
- -49.23%
News
benzinga.com MapLight Therapeutics Q3 EPS $(0.97) Beats $(1.16) Estimate MapLight Therapeutics (NASDAQ:MPLT) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.16) by 16.38 percent. This is a 97.39 percent increase over losses…
globenewswire.com MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028
globenewswire.com MapLight Therapeutics to Participate in Upcoming Investor Conference SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers SCWorx (NASDAQ:WORX) stock rose 47.8% to $3.96 during Tuesday's pre-market session. Integra Lifesciences (NASDAQ:IART) shares increased by 31.97% to $17.75. The market value of their…
